07:09 AM EDT, 09/13/2024 (MT Newswires) -- GSK (GSK) said Friday its blood cancer drug, Blenrep, was granted a breakthrough therapy designation in China.

China's National Medical Products Administration gave the designation to Blenrep combined with the injectable bortezomib plus the steroid dexamethasone, GSK said.

Breakthrough therapy designation will help expedite the development and approval of the indication in China.

Price: 43.27, Change: +0.16, Percent Change: +0.37